In Brief: Cyberonics
This article was originally published in The Gray Sheet
Executive Summary
Cyberonics: Submits PMA amendment to FDA for its NCP neurocybernetic prosthesis system, including information on the device's "safety and efficacy, the statistical treatment of study data, and other clinical and technical issues." FDA had requested in October that Cyberonics withdraw the PMA pending completion of an additional clinical study on the device, but the agency "has agreed" that the PMA "need not be voluntarily withdrawn" in light of the data submission. FDA also has authorized the company to begin the clinical study of an additional 200 patients, which will provide "confirmatory data" to the firm's initial clinical trial results. The implantable, vagus nerve stimulation device is intended to treat epilepsy patients "experiencing refractory partial seizures"...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.